Skip to main content
John Sloan, MD, Hematology, Boston, MA

John M Sloan MD

Clotting Disorder, Hematologic Oncology


Associate Professor, Medicine, Boston University School of Medicine

Join to View Full Profile
  • 830 Harrison AveMoakley, 3rd FloorBoston, MA 02118

  • Phone+1 617-638-6428

  • Fax+1 617-638-5756

Dr. Sloan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Internal Medicine, 2001 - 2004
  • Yale School of Medicine
    Yale School of MedicineClass of 2001
  • Haverford College
    Haverford CollegeBS, Physics, With High Honors, 1992 - 1996

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2005 - 2026
  • CT State Medical License
    CT State Medical License 2004 - 2005
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Hematology
    American Board of Internal Medicine Hematology
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Evans Quality Improvement Award Boston University, 2013
  • Physician Scholar in International Health Johnson and Johnson, 2003
  • American Cancer Society Award American Cancer Society, 2001
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Heparin-Induced Thrombocytopenia and Thrombosis During High Dose Melphalan and Autologous Stem Cell Transplantation  
    Dina Brauneis, Vaishali Sanchorawala, J Mark Sloan, Shayna Sarosiek, Blood
  • Beyond Methotrexate: Treatment of Residual Disease in Primary Central Nervous System Lymphoma  
    Sloan JM, Hochberg E, Hochberg F, The American Journal of Hematology/Oncology, 1/1/2007
  • Contrast mechanisms for scanning tunneling microscopy of biological molecules  
    Sloan JM and Smith WF, Probe Microscopy, 1/1/1997
  • Join now to see all

Books/Book Chapters

Abstracts/Posters

  • The Effect of Anticoagulant Choice on Venous Thromboembolism Recurrence and Bleeding in Sickle Cell Disease
    John Mark Sloan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Patients with Sickle Cell Disease and Venous Thromboembolism Experience Increased Frequency of Vasoocclusive Events
    John Mark Sloan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Successful Transition from Bortezomib Subcutaneous (SubQ) to Generic Intravenous (IV) Bortezomib: Cost Savings Initiative with Global Economic Impact
    John Mark Sloan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Safety, Tolerability and Response Rates of Daratumumab in Patients with Relapsed Light Chain (AL) Amyloidosis: Results of a Phase II Study 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • "Guest Speaker" 
    Miami, FL - 1/10/2015
  • "Medical Marijuana in Oncology: Benefits and potential pitfalls." 
    6/18/2014
  • Join now to see all

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: